2026-01-26 - Analysis Report
**AbbVie (ABBV) Analysis Report**
=====================================

**Company Overview**
-------------------

AbbVie is a global biopharmaceutical company with a diversified portfolio of innovative therapies.

**Return Rate Comparison**
---------------------------

| Ticker | Cumulative Return |
|--------|--------------------|
| ABBV   | 180.27% |
| VOO    | 126.41% |

The cumulative return of AbbVie (ABBV) is **53.86%** higher than the S&P 500 (VOO) on the last day of the data, indicating a significant divergence.

**Alpha, Beta Analysis**
------------------------

| Year      | CAGR  | MDD  | Alpha | Beta | Cap(B) |
|-----------|-------|------|-------|------|--------|
| 2016-2018 | 35.0% | 23.1% | 23.0% | 1.0 | 162.9B |
| 2017-2019 | 27.0% | 23.1% | 2.0%  | 1.1 | 156.5B |
| 2018-2020 | -19.0%| 32.9% | -43.0%| 0.8 | 189.4B |
| 2019-2021 | 77.0% | 32.9% | 12.0% | 0.7 | 239.3B |
| 2020-2022 | 100.0%| 32.9% | 93.0% | 0.6 | 285.6B |
| 2021-2023 | 54.0% | 19.5% | 33.0% | 0.4 | 273.9B |
| 2022-2024 | 33.0% | 19.5% | 3.0%  | 0.3 | 314.1B |
| 2023-2025 | 84.0% | 20.4% | 9.0%  | 0.3 | 403.8B |

**Recent Stock Price Fluctuations**
---------------------------------

| Metric  | Value    |
|---------|----------|
| Close   | $219.26 |
| Last-market |{'price': 219.26, 'previousClose': 218.11, 'change': 0.53} |
| 5-day SMA | $216.38 |
| 20-day SMA | $223.07 |
| 60-day SMA | $225.05 |

The stock price has shown a **$0.53** price increase in the last market day, which reflects a relatively sharp rebound.

**RSI, PPO Index Indicators**
------------------------------

| Indicator | Value    |
|-----------|----------|
| RSI       | 40.08    |
| PPO       | -0.25    |
| MRI       | 0.70     |

The RSI and PPO indicators suggest a relatively low risk investment, with a MRI of 0.70 indicating a medium risk investment.

**Recent News & Significant Events**
------------------------------------

1. What to Expect From AbbVie's Next Quarterly Earnings Report - Yahoo Finance (link)
2. Commerzbank Aktiengesellschaft FI Sells 39,586 Shares of AbbVie Inc. $ABBV - MarketBeat (link)
3. 3 No-Brainer Dividend Stocks to Buy Right Now - The Motley Fool (link)
4. AbbVie is a top dividend stock as drug pipelines drive payout hikes - thestreet.com (link)
5. How Investors Are Reacting To AbbVie (ABBV) Expanding Its Bispecific Oncology And Obesity Treatment Pipeline - simplywall.st (link)
6. AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq (link)

**Analyst Opinions**
-------------------

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 245.22 / 289.00 / 184.00

**Comprehensive Analysis**
-------------------------

Based on the analysis, AbbVie (ABBV) has a high rate of return compared to the S&P 500, with a cumulative return of 53.86% higher. The stock price has shown strong fluctuations, and the RSI and PPO indicators suggest a relatively low risk investment. Recent news indicates significant events in the company, including the expansion of its drug pipeline. Analyst opinions suggest a buy recommendation, with a target price of $245.22. Overall, the comprehensive analysis suggests a potentially strong investment opportunity in AbbVie (ABBV).

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.